New DOT1L Focused Library

Screening compounds for **epigenetic drug discovery**

As a Director of Otava Ltd. I would like to offer you our new **DOT1L Focused Library (1,625 compounds in total)** which is designed to target human histone lysine methyltransferase DOT1L.

Histone methyltransferases are promising epigenetic drug targets. Several drugs that inhibit histone methyltransferases have been developed for anticancer therapy. DOT1L histone H3 methyltransferase methylates lysine 79 on histone H3 (H3K79), within the globular histone domain upon which DNA is wrapped. DOT1L is an attractive target for specific malignancies, such as leukemia. Inhibitors of DOT1L could potentially be used for anticancer therapy.

Otava's new **DOT1L Focused Library** has been carefully designed with receptor-based approach that included docking of **Drug-like Green Coollection** in the active site of human DOT1L (crystal structure of complex with inhibitor FED2, PDB ID 4EQZ) and filtering by score values and hydrogen bonds formed between ligand and key residues of the DOT1L active site. The library **comprises drug-like compounds only.**

All compounds are in stock (20mg min. amount).

Find out more...

Example price list in USD:

Num. of compounds ordered	1-10	11-20	21-50	51-100	101-500	501-1000
Price for 1mg	$38.3	$32.7	$21.5	$19.4	$12.2	$9.5

We offer **15% Academic Discount** for the Fragment Library until Dec 31, 2013

The library is for prompt delivery, cherry-picking is available.

Feel free to contact me if you are interested to obtain this library or if you need more information. I am looking forward to your reply.

Best regards,
Andriy Dmytrenko, MBA
Director of Business Development and Marketing

OTAVA Ltd.
Tel.: 1-416-549-8030
Fax: 1-866-881-9921 (Toll-free in US & Canada)
info@otavachemicals.com
north.america@otavachemicals.com